July 30, 2025 · Form 4 insider transaction
EcoR1 Capital, LLC sold 27,433,338 shares of ADAPTIMMUNE THERAPEUTICS PLC at $0.10 per share, a transaction worth $2.80M. The trade was recorded as open-market sale and disclosed on an SEC Form 4, filed 0 days after the transaction.
These Ordinary Shares are held through American Depositary Shares ("ADS") of the Issuer. Each ADS represents 6 Ordinary Shares.; The reporting persons sold 4,572,223 ADSs representing 27,433,338 Ordinary Shares. Qualified Fund sold 4,270,000 of those ADSs, representing 25,620,000 Ordinary Shares.; The price reported in Column 4 is the price per ADS sold by the reporting persons.; After this transaction, the reporting persons beneficially owned 16,728,647 ADSs, including 15,881,331 ADSs held by Qualified Fund representing 95,287,986 Ordinary Shares.; The reporting persons are EcoR1 Capital, LLC ("Ecor1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Fund"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.